Does Semaglutide Cause Erectile Dysfunction?

Does semaglutide cause erectile dysfunction? We don't yet know whether it directly causes trouble getting or keeping an erection. Some men report problems during treatment, but studies point in different directions. The current Ozempic and Wegovy labels don't list it as a side effect.

That doesn't make a new problem imaginary. Erection changes deserve a medical review, including possible causes beyond the medicine.

Does semaglutide cause erectile dysfunction? The label record

Semaglutide belongs to the GLP-1 family, medicines that copy a gut hormone involved in appetite and blood sugar. Ozempic and Wegovy contain semaglutide. Zepbound contains tirzepatide, a medicine acting on two gut-hormone signals.

As of October 29, 2026, the day this article was written, these FDA prescribing documents do not list erectile dysfunction in section 6.1, covering trials, or 6.2, covering reports after marketing:

A missing label entry doesn't prove that a reaction cannot happen. It means erectile dysfunction isn't an established labeled reaction in these documents.

What the semaglutide study actually counted

Able and colleagues' TriNetX medical-record study, published in the International Journal of Impotence Research in 2025, compared 3,094 semaglutide recipients with 3,094 nonusers with similar recorded health characteristics. They were men aged 18–50 with obesity and without diabetes or previous erectile dysfunction.

The outcome combined a new erection-problem diagnosis or a new prescription for medicines such as sildenafil. It wasn't a questionnaire asking every man about his erections.

That outcome appeared in about 15 per 1,000 semaglutide recipients versus 3 per 1,000 nonusers: 1.47% versus 0.32%. That gap works out to roughly 11 to 12 more recorded cases per 1,000 men. The authors reported a risk ratio of 4.5, comparing the two groups' risks, with a wide uncertainty range of 2.3 to 9.0.

Those are associations, not proof of cause. Differences in health, treatment selection and opportunities to report symptoms can remain after matching. The 1.47% figure is an observed study result, not a one-year forecast for every man taking semaglutide. Our relative and absolute risk guide explains why the starting numbers matter.

Why side-effect reports give different answers

The FDA Adverse Event Reporting System, or FAERS, collects suspected medicine reactions. A report records a concern; it doesn't establish what caused it.

Pourabhari Langroudi and colleagues, International Journal of Impotence Research, 2025, counted 182 reports across several GLP-1 medicines involving erections, orgasm or reduced desire. Their reporting odds ratio, a comparison of reporting patterns, was 0.41: below the database comparison, rather than an excess.

As of October 29, 2026, the day this article was written, a newer Andrology analysis published March 26, 2026 found 49 semaglutide-associated erection-problem reports and a reporting odds ratio of 1.53, pointing the other way. It found almost the same ratio for two diabetes medicines outside the GLP-1 family, sitagliptin and dapagliflozin, and none for dulaglutide, and its authors called the findings preliminary.

The analyses counted different outcomes and medicines. Neither had a count of all treated men, including those without symptoms. These ratios cannot tell someone their chance of developing erectile dysfunction, or prove harm or protection.

What about tirzepatide and Mounjaro?

Cowart and colleagues' 2025 Journal of Diabetes and Its Complications study reviewed medical records of men aged 18–70 with type 2 diabetes. Tirzepatide, the medicine in Mounjaro and Zepbound, was associated with fewer new erection-problem diagnoses or prescriptions than semaglutide, sitagliptin or dulaglutide.

This was a matched observational comparison: researchers balanced recorded characteristics rather than assigning treatments by chance. It doesn't establish tirzepatide as an erection treatment or show that switching would solve an individual's symptoms. Any decision about continuing or changing a GLP-1 medicine belongs with the prescriber.

Can erectile function improve instead?

Some evidence points toward improvement. Kounatidis and colleagues' Biomolecules review, 2025, describes possible benefits through weight loss, blood-sugar control and blood-vessel health. Those pathways are plausible, but don't predict an individual's response.

In the REWIND trial's exploratory analysis, The Lancet Diabetes & Endocrinology, 2021, 3,725 men over 50 with type 2 diabetes completed erection questionnaires. New moderate-to-severe problems occurred at rates of 21.3 versus 22.0 per 100 person-years with dulaglutide versus placebo, an inactive treatment — a slightly lower rate (hazard ratio 0.92) that the authors said might reflect a small benefit. Person-years combine participants' time under observation. This tested a different medicine, not semaglutide.

As of October 29, 2026, the day this article was written, Mirghani and AlQurashi's September 20 review in World Journal of Methodology reports a pooled 2.73-point improvement in sexual-function scores. Its 95% confidence interval, a range expressing uncertainty around the estimate, was 1.64–3.83 points.

It pooled seven comparisons under six references, covering liraglutide, dulaglutide, tirzepatide and unspecified GLP-1 treatment. It didn't isolate semaglutide. The authors rated the evidence very low; the paper also gives conflicting participant totals and search dates. That result needs caution.

Why two people can have different experiences

Obesity and diabetes can themselves affect erections through blood vessels, nerves and hormones. They also influence who receives these medicines. Researchers call that confounding: another factor can help explain an apparent medicine effect.

Testosterone, a hormone involved in sexual function, may change with weight loss, but a blood-test change doesn't guarantee better erections. Semaglutide and testosterone covers that separate question.

Mood, sleep, relationship strain and other medicines can matter too. Reduced desire isn't the same as difficulty maintaining an erection. The semaglutide and depression evidence addresses mood concerns without assuming the medicine caused them.

What a clinician considers when erections change

The American Urological Association guideline, Journal of Urology, 2018, treats erectile dysfunction as a possible marker of underlying heart or blood-vessel disease. A review considers symptom timing, morning erections, medical and sexual history, mood, medicines, examination and selected blood tests.

Its treatment options include counseling, medicines such as sildenafil or tadalafil that support penile blood flow, vacuum devices, local medicines and implants. The choice depends on the cause, health history and preferences. Nitrates, medicines used for certain heart problems, can cause a dangerous blood-pressure fall with sildenafil or tadalafil.

PT-141 isn't among the guideline's listed options; its evidence in men is limited, and the largest published trial in men, a 2008 study of 342 men, carries a 2023 expression of concern: a journal notice flagging doubts about the study.

What the prescription review means

Semaglutide, tirzepatide and PT-141 through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications, meaning prepared for a prescription. They are different from FDA-approved products: the formulations offered here are not FDA-approved. FDA explains that it doesn't review these preparations for safety, effectiveness or quality before marketing.

A licensed provider may still prescribe — that decision is between you and your doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.

New erection problems give that clinician something specific to evaluate. They don't, by themselves, identify the cause or decide which prescription fits.